Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Guruprasad P Aithal, Professor 0044 01158231149
guru.aithal@nottingham.ac.uk


Noor K Al-Tameemi, PhD student candidate 0044 01158231149
noorkifahabdulhussein.al-tameemi@nottingham.ac.uk


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Back

The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Recruiting

Open to: ALL

Age: 18.0 - N/A

Nottingham Nottingham Nottingham

Medical Conditions

Nonalcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver Disease (NAFLD)
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
MASLD
NAFLD
Metabolic Dysfunction-Associated Steatotic Liver Disease
NAFLD (Nonalcoholic Fatty Liver Disease)
NAFLD (Non-alcoholic Fatty Liver Disease)
NAFLD - Non-Alcoholic Fatty Liver Disease
NAFLD - Nonalcoholic Fatty Liver Disease

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The goal of this clinical trial is to learn if daily supplementation with Low-methoxy (LM) pectin (polysaccharides extracted from citrus peels), which are commonly found in the UK diet (not pharmacological agents), can reduce systemic inflammation and improve gut microbiota composition in adults recently diagnosed with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The main question it aims to answer is:

-How does dietary Low-methoxy (LM) pectin supplementation affect systematic inflammation pathways such as those mediated by gut microbiota composition and what are the impacts on general metabolic indicators in individuals with MASLD?

Researchers will compare a group taking 15g of LM-pectin with 10g of cocoa powder to a placebo group receiving 10g of placebo with 10g of cocoa powder to see if LM-pectin has measurable effects on inflammation and gut microbiota.

Participants will:

* Take a daily supplement for 6 weeks: either 15g of LM-pectin with 10g of cocoa powder (intervention), or 10g of placebo with 10g of cocoa powder (control) * Provide stool and fasting blood samples before and after the intervention * Undergo anthropometric measurements (weight, height, waist/hip ratio, and blood pressure) * Complete a case report form (CRF) including demographics and health/medical history * Undergo a FibroScan™ to assess liver health * (Optional) Participate in MRI scans to evaluate gut permeability

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Jun 2025 Mar 2027

INTERVENTIONAL

Intervention Type : DIETARY_SUPPLEMENT
Intervention Description : 15g of pectin with 10g of cocoa powder added as flavour were randomly allocated to eligible participants.

Intervention Arm Group : Pectin;

Intervention Type : OTHER
Intervention Description : 10g of cocoa powder served as the control/ placebo to compare the effects observed with pectin.

Intervention Arm Group : Cocoa Powder;

Intervention Type : DIAGNOSTIC_TEST
Intervention Description : To validate MRI scans as a tool to assess intestinal wall thickness to indicate gut permeability on MASLD patients, the investigators will scan 15 healthy volunteers twice, at baseline and after 6 weeks, and then compare their results with MASLD participant results at baseline and after 6 weeks.

Intervention Arm Group : Magnetic resonance imaging (MRI) Validation;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • University of Nottingham
    Nottingham
    NG7 2UH
  • Sir Peter Mansfield Imaging Centre, University of Nottingham
    Nottingham
    NG7 2QX
  • Nottingham Clinical Research Facility at Nottingham University Hospitals NHS Trust
    Nottingham
    NG7 2UH

Noor K Al-Tameemi, PhD student candidate 0044 01158231149
noorkifahabdulhussein.al-tameemi@nottingham.ac.uk


Guruprasad P Aithal, Professor 0044 01158231149
guru.aithal@nottingham.ac.uk



The study is sponsored by University of Nottingham and is in collaboration with Nottingham University Hospitals NHS Trust.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT07093346
Last updated 22 July 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top